Howmanypatents

Sign in Subscribe

Latest — Jul 1, 2025

Lilly hedges IP risk in $1.3bn Verve acquisition

Eli Lilly has announced its intention to acquire Verve Therapeutics for approximately US$1.3 billion, aiming to accelerate development of one-time gene-editing treatments for cardiovascular disease. The acquisition builds on a pre-existing collaboration between the two companies focused on in vivo gene editing and positions Lilly to compete more

More issues

IonQ to acquire Oxford Ionics: IP play, market access—or something more?

IonQ and Oxford Ionics have announced they have entered into a definitive agreement for IonQ to acquire Oxford Ionics in a transaction valued at US$1.075 billion, which will consist of US$1.065 billion in shares of IonQ common stock and approximately US$10 million in cash (subject

Regeneron acquires 23andMe to access DNA profiling IP

Regeneron Inc has announced it has entered into an Asset Purchase Agreement to acquire 23andMe for US$ 256 Million. The planned purchase aims to strengthen Regeneron’s ongoing leadership in genetics-guided research and drug development to help people with serious diseases. Regeneron has stated that it plans to: * maintain the

Softbank to acquire Ampere Computing in US$ 6.5 billion deal

Ampere Computing will operate as a wholly owned subsidiary of SoftBank Group and retain its name. The deal is expected to be closed in the latter half of 2025. Ampere Computing is engaged in developing high-performance, energy-efficient processors tailored for cloud computing and AI workloads. The company currently employs around

Google to acquire Wiz - the company's most expensive deal to date

Google announced it has signed a definitive agreement to acquire Wiz, Inc., a leading cloud security platform headquartered in New York, for US$ 32 billion, in an all-cash transaction. Once closed, Wiz will join Google Cloud. Google said this acquisition represents an investment by Google Cloud to accelerate two large

Cortigent’s Patent Portfolio: Aging IP or Strategic Reset?

Vivani Medical has announced plans to spin off Cortigent as an independent publicly-traded company. The spin-off is planned to be completed by Q3 2025. Vivani Medical was formed in 2022 through the merger of Second Sight Medical and Nano Precision Medical. Cortigent, previously known as Second Sight Medical Products, has

2Seventybio to be acquired by Bristol Myers Squibb for US$286 million in cash deal

2Seventybio has announced a definitive merger agreement under which Bristol Myers Squibb (BMS) will acquire the company in an all-cash transaction for a total equity value of approximately US$ 286 million. The transaction has been approved by both companies and is expected to close in Q2 of this year. 2Seventybio

Jazz Pharmaceuticals acquires Chimerix for approximately US$935 million in cash

Through the acquisition Jazz Pharmaceuticals gains access to dordaviprone, a novel small molecule therapy in development for H3 K27M-mutant diffuse glioma in children and young adults. The transaction has been approved by both companies and is expected to close in Q2 of this year. The acquisition sees Jazz Pharmaceuticals gain

Bluebird bio to be acquired by Carlyle and SK Capital

According to report the company has been acquired for about US$30 million. Carlyle and SK Capital will provide primary capital to scale Bluebird’s commercial delivery of gene therapies for patients with sickle cell disease, β-thalassemia, and cerebral adrenoleukodystrophy. Bluebird Bio has had 900+ patent applications, and 200 granted

A US$ 250 million Play for Spinal Stimulation Patents

Globus Medical announced its US$ 250 million acquisition of Nevro on February 6, 2025, gaining control of their large spinal cord stimulation (SCS) patent portfolio. This acquisition expands Globus' neuromodulation patent portfolio and strengthens its position in the US$13.3 billion spinal device market. A market that is